Otilonium bromide

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Otilonium bromide
Otilonium bromide.png
Clinical data
Trade names Spasmoctyl 40, Doralin
AHFS/Drugs.com International Drug Names
ATC code
Identifiers
PubChem CID
ChemSpider
UNII
KEGG
ECHA InfoCard 100.043.128
Chemical and physical data
Formula C29H43BrN2O4
Molar mass 563.57 g/mol
3D model (JSmol)
 NYesY (what is this?)  (verify)

Otilonium bromide is an antimuscarinic and calcium channel blocker used to relieve spasmodic pain of the gut, especially in irritable bowel syndrome.[1]

Medical uses[edit]

A pooled analysis of three clinical trials suggest that otilonium is more effective than placebo for the treatment of irritable bowel syndrome.[2]

Pharmacology[edit]

Otilinium binds to both muscarinic receptors and tachykinin NK2 receptors.[3] It has been shown to inhibit L-type and T-type calcium channels, actions which may contribute to or determine its effects in the gut.[4][5]

When taken orally, very little of the drug is absorbed into the rest of the body,[6] which means that most of its actions remain confined to the gastrointestinal system.

References[edit]

  1. ^ "Dismox" (PDF). Archived from the original (PDF) on 4 March 2016. 
  2. ^ Clavé, P; Tack, J (March 2017). "Efficacy of otilonium bromide in irritable bowel syndrome: a pooled analysis". Therapeutic advances in gastroenterology. 10 (3): 311–322. doi:10.1177/1756283X16681708. PMID 28246548. 
  3. ^ Evangelista, S (1999). "Otilonium bromide: a selective spasmolytic for the gastrointestinal tract". The Journal of international medical research. 27 (5): 207–22. doi:10.1177/030006059902700501. PMID 10689627. 
  4. ^ Martin, MT; Hove-Madsen, L; Jimenez, M (April 2004). "Otilonium bromide inhibits muscle contractions via L-type calcium channels in the rat colon". Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society. 16 (2): 175–83. doi:10.1111/j.1365-2982.2004.00518.x. PMID 15086871. 
  5. ^ Strege, PR; Sha, L; Beyder, A; Bernard, CE; Perez-Reyes, E; Evangelista, S; Gibbons, SJ; Szurszewski, JH; Farrugia, G (May 2010). "T-type Ca(2+) channel modulation by otilonium bromide". American Journal of Physiology. Gastrointestinal and Liver Physiology. 298 (5): G706–13. doi:10.1152/ajpgi.00437.2009. PMID 20203058. 
  6. ^ Shin, BS; Kim, JJ; Kim, J; Hu, SK; Kim, HJ; Hong, SH; Kim, HK; Lee, HS; Yoo, SD (January 2008). "Oral bioavailability and enterohepatic recirculation of otilonium bromide in rats". Archives of pharmacal research. 31 (1): 117–24. PMID 18277617.